$6.20
1.14% today
Nasdaq, Apr 03, 06:42 pm CET
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Atara Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation

Atara Biotherapeutics Inc Classifications & Recommendation:

Buy
67%
Hold
33%

Atara Biotherapeutics Inc Price Target

Target Price $13.25
Price $6.13
Potential
Number of Estimates 4
4 Analysts have issued a price target Atara Biotherapeutics Inc 2026 . The average Atara Biotherapeutics Inc target price is $13.25. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 4 Analysts recommend Atara Biotherapeutics Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Atara Biotherapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Atara Biotherapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 128.94 76.75
1,404.55% 40.48%
EBITDA Margin -58.66% -23.45%
98.10% 60.02%
Net Margin -51.86% -44.13%
98.84% 14.90%

6 Analysts have issued a sales forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc sales estimate is

$76.7m
Unlock
. This is
40.48% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$155m 20.21%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $129m 1,404.55%
2025
$76.7m 40.48%
Unlock
2026
$71.8m 6.41%
Unlock
2027
$150m 109.37%
Unlock
2028
$201m 33.55%
Unlock
2029
$167m 16.93%
Unlock

1 Analyst has issued an EBITDA forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc EBITDA estimate is

$-18.0m
Unlock
. This is
75.64% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-18.0m 75.64%
Unlock
, the lowest is
$-18.0m 75.64%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-75.6m 71.40%
2025
$-18.0m 76.20%
Unlock
2026
$-71.0m 294.44%
Unlock
2027
$-56.0m 21.13%
Unlock
2028
$-137m 144.64%
Unlock
2029
$-118m 13.87%
Unlock

EBITDA Margin

2024 -58.66% 98.10%
2025
-23.45% 60.02%
Unlock
2026
-98.85% 321.54%
Unlock
2027
-37.24% 62.33%
Unlock
2028
-68.22% 83.19%
Unlock
2029
-70.73% 3.68%
Unlock

2 Atara Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Atara Biotherapeutics Inc net profit estimate is

$-33.9m
Unlock
. This is
55.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-20.2m 73.19%
Unlock
, the lowest is
$-47.5m 36.99%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-66.9m 82.49%
2025
$-33.9m 49.34%
Unlock
2026
$-30.0m 11.51%
Unlock
2027
$-43.5m 45.28%
Unlock
2028
$-61.5m 41.25%
Unlock
2029
$-115m 87.04%
Unlock

Net Margin

2024 -51.86% 98.84%
2025
-44.13% 14.90%
Unlock
2026
-41.73% 5.44%
Unlock
2027
-28.95% 30.63%
Unlock
2028
-30.62% 5.77%
Unlock
2029
-68.95% 125.18%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -11.41 -5.78
82.49% 49.34%
P/E negative
EV/Sales 1.01

2 Analysts have issued a Atara Biotherapeutics Inc forecast for earnings per share. The average Atara Biotherapeutics Inc EPS is

$-5.78
Unlock
. This is
55.09% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.45 73.19%
Unlock
, the lowest is
$-8.11 36.99%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-11.41 82.49%
2025
$-5.78 49.34%
Unlock
2026
$-5.12 11.42%
Unlock
2027
$-7.43 45.12%
Unlock
2028
$-10.50 41.32%
Unlock
2029
$-19.63 86.95%
Unlock

P/E ratio

Current -0.48 92.00%
2025
-1.06 120.83%
Unlock
2026
-1.20 13.21%
Unlock
2027
-0.83 30.83%
Unlock
2028
-0.58 30.12%
Unlock
2029
-0.31 46.55%
Unlock

Based on analysts' sales estimates for 2025, the Atara Biotherapeutics Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.60 94.62%
2025
1.01 67.95%
Unlock
2026
1.08 6.86%
Unlock
2027
0.51 52.24%
Unlock
2028
0.39 25.12%
Unlock
2029
0.46 20.38%
Unlock

P/S ratio

Current 0.28 97.34%
2025
0.47 67.98%
Unlock
2026
0.50 6.86%
Unlock
2027
0.24 52.23%
Unlock
2028
0.18 25.12%
Unlock
2029
0.22 20.35%
Unlock

Current Atara Biotherapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Canaccord Genuity
Locked
Locked
Locked Mar 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 22 2025
Canaccord Genuity
Locked
Locked
Locked Jan 17 2025
Rodman & Renshaw
Locked
Locked
Locked Dec 20 2024
Canaccord Genuity
Locked
Locked
Locked Nov 13 2024
HC Wainwright & Co.
Locked
Locked
Locked Aug 21 2024
Analyst Rating Date
Locked
Canaccord Genuity:
Locked
Locked
Mar 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 22 2025
Locked
Canaccord Genuity:
Locked
Locked
Jan 17 2025
Locked
Rodman & Renshaw:
Locked
Locked
Dec 20 2024
Locked
Canaccord Genuity:
Locked
Locked
Nov 13 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 21 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today